Additionally, results from a Phase 2 clinical trial using rituximab in new-onset T1D patients showed that patients treated with the B-cell-depleting anti-CD20 monoclonal antibody exhibited preserved C-peptide and a decreased exogenous insulin dosage compared to placebo-treated patients one year after therapy [6,7]. This evidence concerns the gene INS and type 1 diabetes mellitus.